Summary
This NCCN Guidelines Insights paper presents the 2024 updates to clinical recommendations for bladder cancer management, the sixth most common cancer in the United States. The document aligns with the fifth edition WHO Classification of Tumours and introduces new treatment strategies for BCG-unresponsive non-muscle-invasive bladder cancer and advanced metastatic disease. These guidelines synthesise current evidence to stratify management across three distinct disease categories with differing prognoses and therapeutic aims.
UK applicability
Whilst these are US-based NCCN guidelines, the WHO classification alignment and emerging therapeutic approaches have applicability to UK oncology practice, particularly for National Health Service policy development around bladder cancer treatment pathways. However, UK clinicians would typically reference NICE guidance and European Association of Urology guidelines alongside these US recommendations.
Key measures
Clinical classification systems, treatment protocols, WHO tumour classification alignment, therapeutic recommendations for NMIBC and metastatic disease
Outcomes reported
The paper details updated NCCN clinical guidelines for bladder cancer management across three disease categories: non-muscle-invasive, muscle-invasive nonmetastatic, and metastatic disease. It reports new treatment recommendations including emerging options for BCG-unresponsive cases and systemic therapy updates for advanced disease.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.